Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Inhalte:

  • => Welche Forschungsthemen werden an der Medizinischen Universität bearbeitet?.
  • => Wer ist daran beteiligt und welche Methoden werden angewandt?.
  • => Welche Fördergeber unterstützen welche Projekte?.
  • => Wo werden Forschungsergebnisse publiziert?.

Facts and Figures: 2.392 Forscher*innenprofile (davon 859 mit ORCID-ID), 6.946 Forschungsprojekte, 138.641 Publikationen, Posters und Vorträge, 54.904 Volltextlinks (davon Volltext frei zugänglich: > 23.465 (Open Access) )

Aktuelle Zitierungen im Web of Science: 1.506.161, davon 2.990 citation classics (>=100 Zitierungen) Summe Altmetrics Score: 201.527

Aktuell durch Fördergeber bewilligte Forschungsprojekte:

Mutations-spezifische Eradikation von Myelofibrose mittels Genom-editierter humaner Stammzellen
Projektleitung: Reinisch Andreas
Laufzeit: 01.11.2021 - 31.10.2024
Geldgeber: Medical Research Future Fund

SFB Lipidhydrolyse (PP05): Zelluläre Lipidabbauwege in Gesundheit und Krankheit - 2. Förderperiode
Projektleitung: Kratky Dagmar
Laufzeit: 01.03.2023 - 28.02.2027
Geldgeber: FWF, Fonds zur Förderung der Wissenschaftlichen Forschung

> Weitere neue Projekte

Die aktuellsten Publikationen in "Top-Journalen" (Top 20 % Impact Ranking):


30.01.2023:

Ahangari, F; Becker, C; Foster, DG; Chioccioli, M; Nelson, M; Beke, K; Wang, X; Justet, A; Adams, T; Readhead, B; Meador, C; Correll, K; Lili, LN; Roybal, HM; Rose, KA; Ding, SZ; Barnthaler, T; Briones, N; DeIuliis, G; Schupp, JC; Li, Q; Omote, N; Aschner, Y; Sharma, L; Kopf, KW; Magnusson, B; Hicks, R; Backmark, A; Dela Cruz, CS; Rosas, I; Cousens, LP; Dudley, JT; Kaminski, N; Downey, GP Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis
AM J RESP CRIT CARE. 2022; 206(12): 1463-1479. Doi: 10.1164/rccm.202010-3832OC
Web of Science PubMed FullText FullText_MUG

 

30.01.2023:

Schumann, K; Mauch, C; Klespe, KC; Loquai, C; Nikfarjam, U; Schlaak, M; Akcetin, L; Kolblinger, P; Hoellwerth, M; Meissner, M; Mengi, G; Braun, AD; Mengoni, M; Dummer, R; Mangana, J; Sindrilaru, MA; Radmann, D; Hafner, C; Freund, J; Rappersberger, K; Weihsengruber, F; Meiss, F; Reinhardt, L; Meier, F; Rainer, B; Richtig, E; Ressler, JM; Holler, C; Eigentler, T; Amaral, T; Peitsch, WK; Hillen, U; Harth, W; Ziller, F; Schatton, K; Gambichler, T; Susok, L; Maul, LV; Laubli, H; Debus, D; Weishaupt, C; Borger, S; Sievers, K; Haferkamp, S; Zenderowski, V; Nguyen, V; Wanner, M; Gutzmer, R; Terheyden, P; Kahler, K; Emmert, S; Thiem, A; Sachse, M; Gercken-Riedel, S; Kaune, KM; Thoms, KM; Heinzerling, L; Heppt, MV; Tratzmiller, S; Hoetzenecker, W; Ollinger, A; Steiner, A; Peinhaupt, T; Podda, M; Schmid, S; Wollina, U; Biedermann, T; Posch, C Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
J EUR ACAD DERMATOL. 2023; Doi: 10.1111/jdv.18779
Web of Science PubMed FullText FullText_MUG

 

30.01.2023:

Cognolato, F; O'Brien, K; Jin, J; Robinson, S; Laun, FB; Barth, M; Bollmann, S NeXtQSM-A complete deep learning pipeline for data-consistent Quantitative Susceptibility Mapping trained with hybrid data
MED IMAGE ANAL. 2023; 84: 102700 Doi: 10.1016/j.media.2022.102700
Web of Science PubMed FullText FullText_MUG

 

30.01.2023:

Bruch, PM; Dietrich, S; Finel, H; Boumendil, A; Greinix, H; Heinicke, T; Bethge, W; Beelen, D; Schmid, C; Martin, H; Castagna, L; Scheid, C; Schafer-Eckart, K; Bittenbring, J; Finke, J; Sengeloev, H; Heiblig, M; Cornelissen, J; Chevallier, P; Mohty, M; Robinson, S; Montoto, S; Dreger, P Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters
LEUKEMIA. 2023; Doi: 10.1038/s41375-022-01782-z
Web of Science PubMed FullText FullText_MUG

 

30.01.2023:

Mynarek, M; Obrecht, D; Sill, M; Sturm, D; Kloth-Stachnau, K; Selt, F; Ecker, J; von Hoff, K; Juhnke, BO; Goschzik, T; Pietsch, T; Bockmayr, M; Kool, M; von Deimling, A; Witt, O; Schuller, U; Benesch, M; Gerber, NU; Sahm, F; Jones, DTW; Korshunov, A; Pfister, SM; Rutkowski, S; Milde, T Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
ACTA NEUROPATHOL. 2023; 145(1): 97-112. Doi: 10.1007/s00401-022-02522-4
Web of Science PubMed FullText FullText_MUG

 

30.01.2023:

Dejaco, C; Landewe, RBM Controversies in rheumatology: telemedicine-friend or foe?
RHEUMATOLOGY. 2023; Doi: 10.1093/rheumatology/keac708
Web of Science PubMed FullText FullText_MUG

 

30.01.2023:

Scotti, A; Pagnesi, M; Kim, WK; Schafer, U; Barbanti, M; Costa, G; Baggio, S; Casenghi, M; De Marco, F; Vanhaverbeke, M; Sondergaard, L; Wolf, A; Schofer, J; Ancona, MB; Montorfano, M; Kornowski, R; Assa, HV; Toggweiler, S; Ielasi, A; Hildick-Smith, D; Windecker, S; Schmidt, A; Buono, A; Maffeo, D; Siqueira, D; Giannini, F; Adamo, M; Massussi, M; Wood, DA; Sinning, JM; Van der Heyden, J; Van Ginkel, DJ; Van Mieghem, N; Veulemans, V; Mylotte, D; Tzalamouras, V; Taramasso, M; Estevez-Loureiro, R; Colombo, A; Mangieri, A; Latib, A Haemodynamic performance and clinical outcomes of transcatheter aortic valve replacement with the self- expanding ACURATE neo2
EUROINTERVENTION. 2022; 18(10): 804-+. Doi: 10.4244/EIJ-D-22-00289
Web of Science PubMed FullText FullText_MUG

 

30.01.2023:

Thomas, D; Wu, M; Nakauchi, Y; Zheng, M; Thompson-Peach, CA; Lim, K; Landberg, N; Köhnke, T; Robinson, N; Kaur, S; Kutyna, M; Stafford, M; Hiwase, D; Reinisch, A; Peltz, G; Majeti, R Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability.
Cancer Discov. 2022; Doi: 10.1158/2159-8290.CD-21-0218
PubMed FullText FullText_MUG

 

27.01.2023:

Theiler-Schwetz, V; Trummer, C; Grübler, MR; Keppel, MH; Zittermann, A; Tomaschitz, A; März, W; Meinitzer, A; Pilz, S Associations of Parameters of the Tryptophan-Kynurenine Pathway with Cardiovascular Risk Factors in Hypertensive Patients.
Nutrients. 2023; 15(2): Doi: 10.3390/nu15020256 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

26.01.2023:

Guger, M; Ransmayr, G; Sonnberger, M; Hametner, S; Weis, S; Berger, T; Enzinger, C Tumefactive multiple sclerosis presents with painless progressive hemiparesis and aphasia.
Lancet. 2023; 401(10372):226 Doi: 10.1016/S0140-6736(22)02305-4
PubMed FullText FullText_MUG

 

26.01.2023:

Blohs, M; Mahnert, A; Brunnader, K; Flucher, C; Castellani, C; Till, H; Singer, G; Moissl-Eichinger, C Acute appendicitis manifests as two microbiome state types with oral pathogens influencing severity.
Gut Microbes. 2023; 15(1):2145845 Doi: 10.1080/19490976.2022.2145845
PubMed FullText FullText_MUG

 

25.01.2023:

Gevaert, P; De, Craemer, J; Bachert, C; Blauwblomme, M; Chaker, A; Cingi, C; Hellings, PW; Hopkins, C; Hox, V; Fokkens, W; Klimek, L; Lund, V; Mösges, R; Mullol, J; Pfaar, O; Scadding, G; Tomazic, PV; Van, Zele, T; Vlaminck, S; Wagenmann, M; Toppila-Salmi, S; Alobid, I European Academy of Allergy and Clinical Immunology Position Paper on Endoscopic Scoring of Nasal Polyposis.
Allergy. 2023; Doi: 10.1111/all.15650
PubMed FullText FullText_MUG

 

25.01.2023:

Pichler, G; Goeral, K; Hammerl, M; Perme, T; Dempsey, EM; Springer, L; Lista, G; Szczapa, T; Fuchs, H; Karpinski, L; Bua, J; Avian, A; Law, B; Urlesberger, B; Buchmayer, J; Kiechl-Kohlendorfer, U; Kornhauser-Cerar, L; Schwarz, CE; Gründler, K; Stucchi, I; Schwaberger, B; Klebermass-Schrehof, K; Schmölzer, GM, , COSGOD, III, study, group Cerebral regional tissue Oxygen Saturation to Guide Oxygen Delivery in preterm neonates during immediate transition after birth (COSGOD III): multicentre randomised phase 3 clinical trial.
BMJ. 2023; 380: e072313 Doi: 10.1136/bmj-2022-072313
PubMed FullText FullText_MUG

 

25.01.2023:

Hodl, I; Sallegger, C; Forstner, P; Sareban, N; Moritz, M; Dreo, B; Schulz, E; Lackner, A; Kleinhappl, B; Hatzl, S; Moazedi-Fürst, F; Seifert-Held, T; Heschl, B; Khalil, M; Enzinger, C; Greinix, H; Stradner, MH; Steinmetz, I; Schlenke, P; Fessler, J Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy.
Microbes Infect. 2023; 105103 Doi: 10.1016/j.micinf.2023.105103 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

24.01.2023:

Ham, L; Montoya, JL; Serrano, V; Yeager, S; Paltin, D; Pasipanodya, EC; Marquine, MJ; Hoenigl, M; Ramers, CB; Kua, J; Moore, DJ High Psychosocial Burden Relates to Poorer Antiretroviral Treatment Adherence Among Black/African American People with HIV.
AIDS Patient Care STDS. 2023; Doi: 10.1089/apc.2022.0180
PubMed FullText FullText_MUG

 

24.01.2023:

Dikaios, I; Althaus, H; Angles-Cano, E; Ceglarek, U; Coassin, S; Cobbaert, CM; Delatour, V; Dieplinger, B; Grimmler, M; Hoofnagle, AN; Kostner, GM; Kronenberg, F; Kuklenyik, Z; Lyle, AN; Prinzing, U; Ruhaak, LR; Scharnagl, H; Vesper, HW; Deprez, L Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays.
Clin Chem. 2023; Doi: 10.1093/clinchem/hvac203
PubMed FullText FullText_MUG

 

> Weitere aktuelle Publikationen in Top-Journals

Distribution of Med Uni Graz affiliated publications by field-normalized Journal Impact Factor (JIFnorm)


Med Uni Graz publications1 were assigned quintiles according to the normalized2 Clarivate’s Journal Impact Factor of the journal at the time of publication.


Proportional Distribution: The color-coded columns show the distribution by JIFnorm-quintiles, while the left vertical axis indicates the proportion relative to the total articles published in a given year. The red line shows the total number of articles published each year (right vertical axis).


JIFnorm: Proportional Distribution


Example 1: Around 40% of the over 500 articles with Med Uni Graz affiliation published in 2019 had a normalized JIF > 0.8 (QU1).
Example 2: The proportion of articles published in journals with a normalized JIF < 0.4 (QU4 and QU5) has remained under 20% since 2010.

Absolute Impact: The sum of the normalized JIFs for all published articles in a given year, color-coded according to the respective quintile.


JIFnorm: Absolut Impact


1 This analysis considered only publications categorized as full papers/original articles.

2 IFnorm = (number of journals in WoS category - ranking of journal + 1) / number of journals in WoS category. An IFnorm of 0.8 means that 20% of the journals in this subject category have a higher IF than the respective journal. The highest possible IFnorm is 1, which means that this journal currently has the highest IF in this subject category.

© Med Uni Graz Impressum